Thursday, October 5 - Saturday, October 7, 2017
Location: Sheraton Seattle
Download the course agenda for more information.
This two-and-a-half-day symposium will provide up-to-date scientific information to clinicians involved in the care of patients with breast or thoracic cancers. Speakers are nationally and internationally renowned clinicians and researchers who will share their expertise and foster discussion of the most recent multidisciplinary advances in screening, pathology, surgery, radiology, medical oncology, chemotherapy, novel targeted therapies, immunotherapies, genetics, and palliative care.
Far-ranging areas of consensus and controversy will be presented and discussed with a goal that audience members leave with the state-of-the-art knowledge needed to maximize success in treating their patients’ breast and thoracic malignancies.
- Discuss the recent advances in thoracic surgery, radiation, and immunotherapy for treating lung cancer.
- Discuss the role for standard radiation and protons for thoracic malignancies disease.
- Review the choice of options for early stage lung cancer.
- Understand new options for small cell lung cancer.
- Discuss the most current systemic therapies for stage IV NSCLC.
- Review treatment options for thymic malignancies.
- Understand advances in multimodality therapy for pleural mesothelioma.
- Discuss value-based health care and the impact of payment reform.
- Describe the pathogenesis, diagnostic evaluation and therapeutic advances for integration into the management of newly diagnosed breast cancer.
- Describe the therapeutic modalities available for advanced breast cancer, and neoadjuvant therapies in particular.
- Describe evidence-based recommendations for supportive care and survivorship.
- Describe how cancer outcomes can vary in different populations and potential reasons why.
- Discuss the impact of medical reform in the realm of oncology.
- Discuss how to manage patients at high risk for breast cancer, especially screening, prevention, and long-term surveillance.
- Navigate and interpret the plethora of available genetic tests and possible results.
- Discuss the ever-changing landscape of known genetic mutations.
- Illustrate the controversy regarding DCIS as a pathologic diagnosis and whether or not it requires local and/or systemic treatment.
- Discuss the role of reconstruction for patients in treatment as well as post-treatment.
This course will benefit health care providers who provide care to breast and/or thoracic cancer patients, including surgeons, radiation oncologists, medical oncologists, pulmonologists, general practitioners, physician assistants, nurse practitioners, oncology nurses, oncology pharmacists, fellows, and other clinical trainees.